Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27843373 | 0.96 | CDK5 (0.45) | CDK5CDK5R1ALDH1A1KDM4EHPGD | |
| SCHEMBL17555856 | 0.83 | MAPT (0.42) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL10075618 | 0.81 | CDK5 (0.46) | CDK5CDK5R1ALDH1A1KDM4EHPGD | |
| SCHEMBL17555814 | 0.80 | CYP2A6 (0.53) | CDK5CDK5R1ALDH1A1KDM4EHPGD | |
| SCHEMBL28145706 | 0.79 | CDK5 (0.45) | CDK5CDK5R1ALDH1A1KDM4EHPGD | |
| SCHEMBL22216730 | 0.79 | NOS3 (0.52) | CDK5CDK5R1ALDH1A1KDM4EHPGD | |
| SCHEMBL1251654 | 0.79 | KDM4E (0.53) | CDK5CDK5R1ALDH1A1KDM4EHPGD | |
| SCHEMBL17555834 | 0.79 | PDE3B (0.42) | CDK5CDK5R1ALDH1A1HPGDADORA2A | |
| SCHEMBL18957021 | 0.79 | CDK5 (0.45) | CDK5CDK5R1ALDH1A1KDM4EHPGD | |
| SCHEMBL27522948 | 0.79 | CDK5 (0.45) | CDK5CDK5R1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11225478-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| CN-110003200-B | P2X7 modulators | 詹森药业有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20200325138-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-15 | — | — | US | disclosed |
| US-10703749-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-07 | — | — | US | disclosed |
| US-20200203630-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2020-06-25 | — | — | US | disclosed |
| EP-3495365-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| US-20190092770-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-28 | — | — | US | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| WO-2012146667-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| CN-1060173-C | Heterocyclic compound with activity against diabetes and preparation and application of same | MITSUTAKA CO LTD (JP) | 2001-01-03 | — | — | CN | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| CN-1118781-A | Heterocyclic compound with activity against diabetes and preparation and application of same | MITSUTAKA CO LTD (JP) | 1996-03-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325138-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | CDK5 1591/4885CDK5R1 1468/4885ALDH1A1 1628/4885 |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | CDK5 3339/4885CDK5R1 3909/4885ALDH1A1 687/4885 |
| US-20190092770-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | CDK5 1591/4885CDK5R1 1468/4885ALDH1A1 1628/4885 |
| US-11225478-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | CDK5 1591/4885CDK5R1 1468/4885ALDH1A1 1628/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | CDK5 1591/4885CDK5R1 1468/4885ALDH1A1 1628/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | CDK5 1591/4885CDK5R1 1468/4885ALDH1A1 1628/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | CDK5 1591/4885CDK5R1 1468/4885ALDH1A1 1628/4885 |
| US-10703749-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | CDK5 1591/4885CDK5R1 1468/4885ALDH1A1 1628/4885 |
| US-20140275015-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | CDK5 1591/4885CDK5R1 1468/4885ALDH1A1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.